Impavido FDA Approval History
FDA Approved: Yes (First approved March 19, 2014)
Brand name: Impavido
Generic name: miltefosine
Dosage form: Capsules
Company: Paladin Labs Inc.
Treatment for: Leishmaniasis
Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.
Development timeline for Impavido
| Date | Article |
|---|---|
| Mar 19, 2014 | Approval FDA Approves Impavido to Treat Tropical Disease Leishmaniasis |
| Nov 13, 2013 | Paladin Announces Extension of the Impavido PDUFA Date by Three Months |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
